All News
#EULAR2021 - Key points from Dr. Mease's oral abstract:
⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD
⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts
⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status
@Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: AxSpA patients more likely to experience IBD and uveitis whereas axPsA more likely to experience dactylitis and enthesitis per Dr. Philip Mease's study among real-world patients in CorEVitas' Psa/Spa Registry.
@RheumNow https://t.co/g2m5fylFJj
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas those w/ predom peripheral phenotype tended to have arthritis, dactylitis, or psoriasis & fit a clinical dx of axSpA & psSpa (incl psA) respectively per this observat study. @RheumNow https://t.co/E5UTbc6Sqb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 bDMARD and TNF-i naive patients w/ r-axSpA without evidence of objective inflammation (normal CRP & MRI ) showed ASA40 response w/ ixekizumab @RheumNow https://t.co/5KT8A81auq
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: Dr. Filip van den Bosch recommends the "DEER" treatment approach for SpA: Dedicated Empathic and Educated Rheumatologist! @RheumNow https://t.co/W0jbGXk7q8
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead!
@RheumNow https://t.co/E61yb97CRN
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021: There is no diagnostic criteria for nr-AxSpA, but there is a diagnostic approach that entails collecting clinical information and imaging to visualize inflammation or post-inflammatory changes of the axial skeleton. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated CRP, negative structural damage on MRI)? @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease burden is less (compared to radiographic-AxSpa)!" Dr. Atul Deodhar @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla
Paul Studenic Stiddyo ( View Tweet)
#Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two ends of the spectrum -- same disease! @RheumNow https://t.co/r0fTtp3Uip
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is similar with equal burden of disease. @RheumNow https://t.co/tm9Y6OB5TY
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Comparison of disease activity and PROs in AxSpA vs. AxPsA
⭐️AxSpA ⬆️ uveitis and IBD
⭐️AxPsA ⬆️enthesitis and dactylitis
⭐️AxSpA pts ⬆️pain, spinal pain PROs
⭐️Fatigue and work impairment did not differ in AxSpA vs AxPsA
Abs#OP0049 #EULAR2021 @RheumNow https://t.co/wGD6IA5ahb
Robert B Chao, MD doctorRBC ( View Tweet)
Secukinumab effective in AS patients, irrespective of gender
AQUILA 52 week study
⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women
⭐️women had overall higher disease burden in global functioning and depressive mood
POS0899
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA
⭐️82% ⬇️ in uveitis flare event
⭐️reduction in axSpA disease activity
⭐️no new safety signals
POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY
Robert B Chao, MD doctorRBC ( View Tweet)
Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx
Dr. Rachel Tate uptoTate ( View Tweet)
In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weight were negative factors in remission. Abstract #OP0052 #EULAR2021 @RheumNow https://t.co/X4wN1wIGfX https://t.co/DKBIXmEmki
Dr. Rachel Tate uptoTate ( View Tweet)